Differential outcomes in codon 12/13 and codon 61 NRAS-mutated cancers in the Phase II NCI-MATCH trial of binimetinib in patients with NRAS-mutated tumors

James M. Cleary, Victoria Wang, Rebecca S. Heist, E. Scott Kopetz, Edith P. Mitchell, James A. Zwiebel, Kevin S. Kapner, Helen X. Chen, Shuli Li, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, Funda Meric-Bernstam, Melissa S. Dillmon, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Andrew J. Aguirre, Peter J. O'DwyerLyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Preclinical and clinical data suggest that downstream inhibition with an MEK inhibitor, such as binimetinib, might be efficacious for NRAS-mutated cancers. Patients and Methods: Patients enrolled in the NCI-MATCH trial master protocol underwent tumor biopsy and molecular profiling by targeted next-generation sequencing. Patients with NRAS-mutated tumors, except melanoma, were enrolled in subprotocol Z1A, a single-arm study evaluating binimetinib 45 mg twice daily. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS) and overall survival (OS). A post hoc analysis examined the association of NRAS mutation type with outcome. Results: In total, 47 eligible patients with a refractory solid tumor harboring a codon 12, 13, or 61 NRAS mutation were treated. Observed toxicity was moderate, and 30% of patients discontinued treatment because of binimetinib-associated toxicity. The ORR was 2.1% (1/47 patients). A patient with malignant ameloblastoma harboring a codon 61 NRAS mutation achieved a durable partial response (PR). A patient with NRAS codon 61-mutated colorectal cancer had an unconfirmed PR, and two other patients with NRAS codon 61-mutated colorectal had stable disease for at least 12 months. In an exploratory analysis, patients with colorectal cancer bearing a NRAS codon 61 mutation (n ¼ 8) had a significantly longer OS (P ¼ 0.03) and PFS (P ¼ 0.007) than those with codon 12 or 13 mutations (n ¼ 16). Conclusions: Single-agent binimetinib did not show promising efficacy in NRAS-mutated cancers. The observation of increased OS and PFS in patients with codon 61 NRAS-mutated colorectal cancer merits further investigation.

Original languageEnglish (US)
Pages (from-to)2996-3004
Number of pages9
JournalClinical Cancer Research
Volume27
Issue number11
DOIs
StatePublished - Jun 1 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Differential outcomes in codon 12/13 and codon 61 NRAS-mutated cancers in the Phase II NCI-MATCH trial of binimetinib in patients with NRAS-mutated tumors'. Together they form a unique fingerprint.

Cite this